Envivo Bio Inc.

Envivo Bio Inc. is a for-profit biotechnology company developing novel ingestible devices and technologies to non-invasively sample and analyze the human gastrointestinal tract, with the goal of advancing gastrointestinal disease research. Through federal grants, the company has focused on developing an ingestible capsule device called Capscan to collect microbiome and metabolome samples from different regions of the GI tract.

Envivo Bio has received over $2.4 million in federal grant funding to support development and testing of the Capscan device. This includes Phase I and Phase II SBIR awards from the National Science Foundation to develop Capscan specifically for inflammatory bowel disease research applications, as well as project grants from the National Institutes of Health National Cancer Institute to support development and clinical evaluation of Capscan for metabolomics monitoring and analysis of gastrointestinal disorders. The grants have supported developing, bench testing and demonstrating safety, reproducibility and regional specificity of the Capscan device. They have also supported clinical studies using Capscan to analyze effects of drugs on the GI microbiome and metabolome, and to measure regional differences in the GI tract of patients with small intestinal bacterial overgrowth before and after antibiotic treatment.